Q2FY23 preview: Modest revenue growth, Ebitda decline seen in pharma cos- QHN

While domestic market demand is strong, analysts expect higher raw material and freight costs to affect business in US, other countries; healthy YoY growth seen in hospitals and diagnostics

Note:- (Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor. The content is auto-generated from a syndicated feed.))

Leave a Reply

Your email address will not be published. Required fields are marked *